Relative Abundance of <i>EGFR</i> Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

Abstract

The relative EGFR mutation abundance could predict benefit from EGFR-TKI treatment for advanced NSCLC.